Profile data is unavailable for this security.
About the company
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is a Turkey-based company, which engages in manufacturing of pharmaceuticals and other health products. The Company operates in the fields of manufacturing all kinds of pharmaceuticals for human use and health products, trading, import and export. Gen Ilac manufactures products used in the treatment of rare diseases and disorders in neurology, endocrinology, nephrology, oncology, hematology and pediatric branches. The Company has approximately 500 employees working in its production facilities on a closed area of 15,000 square meters, established on an area of approximately 43,000 square meters in Ankara ASO 2nd and 3rd Organized Industrial Zone. Entity has 5 offices abroad: Germany, Russia, Kazakhstan, Uzbekistan and Azerbaijan.
- Revenue in TRY (TTM)10.31bn
- Net income in TRY512.01m
- Incorporated1997
- Employees625.00
- LocationGen Ilac ve Saglik Urunleri Sanayi ve Ticaret ASMustafa Kemal Mahallesi 2119.Cad. No:3CankayaANKARA 06520TurkeyTUR
- Phone+90 3 122196219
- Fax+90 3 122196010
- Websitehttps://www.genilac.com.tr
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Guerbet SA | 27.50bn | 835.27m | 15.31bn | 2.92k | 19.24 | 1.15 | 5.25 | 0.5567 | 1.80 | 1.80 | 62.15 | 29.97 | 0.7997 | 0.5983 | 5.80 | 269,071.90 | 2.26 | 1.40 | 2.96 | 1.86 | 78.01 | 76.02 | 2.82 | 1.82 | 1.21 | 5.62 | 0.5035 | 57.82 | 4.30 | -0.0993 | 158.05 | -12.61 | 5.23 | -10.07 |
Pharmanutra SpA | 3.51bn | 378.96m | 15.60bn | 111.00 | 40.79 | 7.77 | 32.61 | 4.44 | 1.13 | 1.13 | 10.43 | 5.93 | 0.9123 | 0.5233 | 4.00 | 955,428.60 | 9.85 | 18.39 | 13.20 | 24.80 | 95.92 | 96.36 | 10.79 | 17.77 | 1.87 | 34.93 | 0.3324 | 52.51 | 21.13 | 16.51 | -14.73 | 8.44 | 75.71 | 11.20 |
Valneva SE | 5.35bn | -853.71m | 15.99bn | 684.00 | -- | 2.41 | 8.93 | 2.99 | -0.1943 | -0.1943 | 1.10 | 1.36 | 0.2799 | 2.34 | 5.63 | 223,622.80 | -4.46 | -15.39 | -6.84 | -25.06 | 32.95 | 35.94 | -15.95 | -34.95 | 2.22 | -2.69 | 0.528 | -- | -57.46 | 6.34 | 29.21 | -- | 35.18 | -- |
Kuros Biosciences AG | 1.23bn | -504.22m | 16.28bn | 80.00 | -- | 7.74 | -- | 13.20 | -0.3697 | -0.3697 | 0.9175 | 1.54 | 0.4347 | 2.40 | 7.27 | 419,550.00 | -17.78 | -13.47 | -21.34 | -14.84 | 71.31 | 78.73 | -40.90 | -81.48 | 1.69 | -84.04 | 0.0364 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
Pharming Group N.V. | 8.45bn | -352.86m | 17.57bn | 415.00 | -- | 2.61 | 61.37 | 2.08 | -0.0162 | -0.0162 | 0.3658 | 0.2858 | 0.5976 | 0.5677 | 7.21 | 581,829.00 | -2.50 | 5.26 | -3.61 | 6.63 | 88.57 | 89.41 | -4.18 | 9.26 | 1.16 | -7.42 | 0.4481 | -- | 19.30 | 9.01 | -177.14 | -- | -13.04 | -- |
Deva Holding AS | 11.33bn | 3.39bn | 18.10bn | 2.91k | 5.35 | 1.22 | 4.45 | 1.60 | 16.93 | 16.93 | 56.65 | 73.92 | 0.5272 | 1.63 | 8.01 | 3,896,257.00 | 15.75 | 14.80 | 23.02 | 21.73 | 41.89 | 41.85 | 29.88 | 24.77 | 1.07 | -- | 0.2706 | 2.36 | 30.04 | 61.21 | 297.79 | 90.10 | 69.34 | -- |
Gen Ilac ve Saglik Urnlr Snyi ve Tcrt AS | 10.31bn | 512.01m | 20.06bn | 625.00 | 39.17 | 3.52 | 24.31 | 1.95 | 1.71 | 1.71 | 34.36 | 18.98 | 1.59 | 11.66 | 9.25 | 16,573,770.00 | 7.71 | 12.39 | 11.25 | 17.53 | 20.64 | 19.06 | 4.85 | 6.95 | 1.15 | 12.95 | 0.2079 | -- | -23.38 | 47.18 | -28.97 | 147.97 | -- | -- |
Basilea Pharmaceutica AG Allschwil | 5.79bn | 383.88m | 20.20bn | 147.00 | 47.63 | -- | 45.63 | 3.49 | 0.8765 | 0.8765 | 13.15 | -0.8335 | 0.7999 | 1.06 | 5.16 | 1,072,340.00 | 5.30 | -1.86 | 7.69 | -2.99 | 83.00 | 83.45 | 6.63 | -2.99 | 2.64 | 2.02 | 1.10 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
Philogen SpA | 809.51m | -215.62m | 20.67bn | 160.00 | -- | 8.98 | -- | 25.54 | -0.1551 | -0.1551 | 0.5747 | 2.25 | 0.1887 | 6.65 | 7.95 | 144,562.50 | -5.03 | -7.32 | -5.56 | -8.36 | 40.04 | 32.04 | -26.64 | -58.66 | 6.84 | -- | 0.1414 | -- | -2.46 | 10.80 | -14.60 | -- | 51.78 | -- |
Boiron SA | 17.26bn | 1.25bn | 21.31bn | 2.81k | 16.82 | 1.53 | 11.00 | 1.23 | 2.06 | 2.06 | 28.41 | 22.67 | 0.715 | 1.40 | 5.26 | 175,533.10 | 4.92 | 4.59 | 6.16 | 5.76 | 72.60 | 74.02 | 6.88 | 6.80 | 1.50 | -- | 0.0338 | 53.86 | -7.67 | -3.98 | -19.80 | -9.01 | -17.68 | -1.42 |
Surgical Science Sweden AB | 2.62bn | 646.96m | 21.61bn | 265.00 | 33.39 | 1.51 | 26.22 | 8.25 | 4.08 | 4.08 | 16.51 | 89.92 | 0.1749 | 1.68 | 6.12 | 3,238,531.00 | 4.32 | 4.49 | 4.59 | 4.78 | 68.59 | 70.06 | 24.70 | 23.75 | 3.53 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
Pharma Mar SA | 5.67bn | 70.91m | 22.50bn | 509.00 | 322.62 | 3.21 | 80.35 | 3.96 | 0.1086 | 0.1086 | 9.10 | 10.92 | 0.4583 | 0.2431 | 6.31 | 318,546.20 | 0.5726 | 18.52 | 0.7699 | 25.89 | 94.30 | 93.76 | 1.25 | 28.87 | 2.14 | -- | 0.17 | -- | -19.45 | 7.77 | -97.70 | -- | 46.37 | -- |
Puretech Health PLC | 108.93m | -2.15bn | 24.98bn | 90.00 | -- | 1.65 | -- | 229.32 | -0.1859 | -0.1859 | 0.0094 | 1.35 | 0.0048 | -- | 0.4676 | 29,175.24 | -9.54 | 4.92 | -10.67 | 5.94 | -- | -- | -2,000.84 | 352.67 | -- | -- | 0.0524 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
Gubra A/S | 961.75m | -208.88m | 25.31bn | 219.00 | -- | 11.21 | -- | 26.32 | -2.91 | -2.91 | 13.51 | 29.44 | -- | -- | -- | 936,095.90 | -- | -- | -- | -- | 56.06 | -- | -21.72 | -- | -- | -- | 0.1296 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Norges Bank Investment Managementas of 31 Dec 2023 | 7.96m | 2.65% |
The Vanguard Group, Inc.as of 30 Apr 2024 | 2.84m | 0.95% |
HSBC Portf�y Y�netim ASas of 30 Apr 2024 | 500.00k | 0.17% |
BlackRock Fund Advisorsas of 06 Jun 2024 | 249.25k | 0.08% |
State Street Global Advisors Ltd.as of 06 Jun 2024 | 174.53k | 0.06% |
Charles Schwab Investment Management, Inc.as of 06 Jun 2024 | 141.10k | 0.05% |
HSBC Asset Management (India) Pvt Ltd.as of 30 Apr 2024 | 130.00k | 0.04% |
Mellon Investments Corp.as of 06 Jun 2024 | 118.45k | 0.04% |
Erste Asset Management GmbHas of 31 Jan 2024 | 90.00k | 0.03% |
SSgA Funds Management, Inc.as of 06 Jun 2024 | 74.10k | 0.03% |